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Progranulin (PGRN), Total-Tau (t-tau), and Neurofilament light chain (NfL) are well known
biomarkers of neurodegeneration. The objective of the present study was to investigate
whether these parameters represent also biomarkers in autoimmune-mediated
Encephalitis (AE) and may give us insights into the pathomechanisms of AE. We
retrospectively examined the concentration of PGRN in the cerebrospinal fluid (CSF) and
serum of 38 patients suffering from AE in acute phase and/or under treatment. This
AE cohort comprises patients with autoantibodies against: NMDAR (n = 18 patients),
Caspr2 (n = 8), Lgi-1 (n = 10), GABAB(R) (n = 1), and AMPAR (n = 1). Additionally, the
concentrations of NfL (n = 25) and t-tau (n = 13) in CSF were measured when possible.
Follow up data including MRI were available in 13 patients. Several age-matched cohorts
with neurological diseases besides neuroinflammation or neurodegeneration served as
control groups. We observed that PGRN was significantly elevated in the CSF of patients
with NMDAR-AE in the acute phase, but normalized at follow up under treatment
(p < 0.01). In the CSF of other patients with AE PGRN was in the range of the CSF
levels of control groups. T-tau was highly elevated in the CSF of patients with temporal
FLAIR-signal in the MRI and in patients developing a hippocampal sclerosis. NfL was
exceptionally high initially in Patients with AE with a paraneoplastic or parainfectious
cause and also normalized under treatment. The normalizations of all biomarkers were
mirrored in an improvement on the modified Rankin scale. The data suggest that the
concentration of PGRN in CSF might be a biomarker for acute NMDAR-AE. Pathological
high t-tau levels may indicate a risk for hippocampal sclerosis. The biomarker properties
of NfL remain unclear since the levels decrease under treatment, but it could not predict
severity of disease in this small cohort. According to our results, we recommend to
measure in clinical practice PGRN and t-tau in the CSF of patients with AE.
Keywords: progranulin, neurofilament light chain, NMDAR encephalitis, Lgi-1 encephalitis, Caspr2 encephalitis,
tau, autoimmune encephalitis
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INTRODUCTION
Since the appearance of antibody-mediated autoimmune
encephalopathy (AE) numerous antibodies (ab) have been
linked to different clinical symptoms such as limbic encephalitis,
faciobrachial dystonic seizures or dementia-like symptoms
(1–3). Biomarkers of neurodegeneration mirror certain
pathomechanisms of neuronal or axonal loss. The measurement
of these biomarkers should bear the potential to provide
useful information in everyday clinical life, e.g., to monitor the
immunosuppressive therapy in Patients with AE. CSF antibody
titres in e.g., contactin-associated-protein-receptor-2 (Caspr2)-
AE or Leucin-rich glioma inactivated ptotein-1 (Lgi-1)-AE do
not mirror the disease course in a linear way (4, 5). Furthermore,
the clinical course in several patients suggests that an antibody
titer independent pathomechanism might take place (6–8).
The underlying mechanisms causing this dichotomy of clinical
symptoms and antibody titer are largely unknown (8). One
possible explanation could be the effect of the long survival of
plasma cells in the brain (9). The brain-resident plasma cells itself
cannot be measured as yet, but the damage possibly caused by
autoantibodies should be detected via biomarkers for neuronal
and axonal loss such as t-tau, PGRN, and NfL.
Recently, a direct connection between neurodegenerative
mechanisms and AE has been detected in AEs mediated by
IgLON5 causing an atypical tauopathy (10). Vice versa a
correlation between autoimmune diseases and Tar DNA-binding
Protein 43 (TDP-43) mediated neurodegeneration in FTD
patients has been reported (11). There is also some debate about
IgA-NMDAR-Abs and IgM-NMDAR-Abs (3, 12, 13) causing
dementia-like symptoms and mimicking neurodegenerative
diseases. Histopathological examinations in patients with AE
have been focused on the immunological mechanisms triggered
and maintained by the antibodies (8) disregarding a systematic
research for markers of neurodegeneration so far. Only one
case report of a Lgi-1 antibody positive patient presenting
some neurodegenerative markers has been reported at autopsy,
without witnessing pathological changes in alpha-synuclein,
beta-amyloid, or neurofibrillary tangle (14). MRI findings and
long-term neuropsychological data also suggest an involvement
of the frontal and temporal lobes in the clinical course of
the NMDAR-AE and voltage-gated-potassium channel (VGKC)-
complex-mediated AE (15–18). Another group has looked at the
glial fibrillary acid, NfL and t-tau levels in patients with suspected
AE (19). Their group only encompassed four patients with
NMDAR-AE and one Lgi-1 patient with most of them having a
status epilepticus (SE) before, as SE is known for confounding
the protein levels in the CSF (20, 21). They found higher NfL
Abbreviations: Ab, Antibody; AD, Alzheimer’s disease; AE, Autoimmune
mediated Encephalitis; AMPAR, alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor; Caspr2, Contactin associated protein
2; CSF, cerebrospinal fluid; FTD, Frontotemporal dementia; GABAB(R),
Gabaaminobutyrat-B subunit receptor; Lgi1, Leucin-rich glioma inactivated
protein1; NMDAR, N-methyl-D-aspartate receptor; NfL, Neurofilament
light chain; PGRN, Progranulin; SE, Status Epilepticus; t-tau, T-tau; VGKC,
Voltage-gated potassium channel.
and t-tau levels in all patients, which is most likely due to the
SE before. In pediatric opsoclonus-myoclonus syndrome caused
by antibodies with intracellular epitopes, immunosuppressive
treatment has shown to decrease the CSF-Neurofilament light
chain levels together with a concomitant clinical improvement
(22, 23).
Here, we examined concentrations of PGRN, NfL, and t-
tau, well-established biomarkers of neurodegeneration, in CSF
and serum of 38 patients with antibody positive AE. The aim
of this study is to investigate if these proteins are possible
biomarkers in Patients with AE. Also, the knowledge about
the biomarkers of neurodegeneration CSF-levels may give clues
about the pathological mechanisms in these patients.
METHODS
Clinical Cohort
This retrospective study was performed according to the
local ethical committees in Berlin, Potsdam, Brandenburg,
Magdeburg and Bielefeld, respectively. All patients gave written
and informed consent (ethics committee approval number
100/16). We included only patients with a proven AE by clinical
symptoms as recommended by Graus et al. (24) and detection
of pathological antibodies with extracellular epitopes via indirect
immunofluorescence tests. The samples of AE-Patients were
collected from April 2013 until October 2017 in Berlin, Potsdam,
Tübingen, Bielefeld, and Magdeburg where their samples were
initially stored at −80◦C and sent to Magdeburg. Every sample
was stored in Magdeburg at −80◦C and all biomarkers were
measured in Magdeburg. All samples were run in duplicate with
the mean taken as result. Samples were measured over time and
not in a batch.
All patients received a lumbar puncture as part of the
diagnostical work up when presenting for the first time
on the ward and for antibody titre control in follow up
depending on each individual disease course. At least 5ml
up to 13ml CSF was taken and serum was collected in
serum separator tubes and centrifuged at site. Every patient
(n = 38) suffered from a limbic encephalitis including its
variants, e.g., limbic encephalitis together with vegetative and/or
peripheral neurological symptoms. All patients improved
under immunosuppressive therapy. Treatment comprised
methylprednisolone (dosage ranges from 3 g up to 18 g during
disease course), cyclophosphamid or rituximab (with aminimum
dosage of 2g), plasmapheresis or ivIG. We had no patients with
a relapse in this cohort. None of the patients had a status
epilepticus before lumbar puncture confounding the biomarker
levels because of neuronal and axonal death due to the status
epilepticus.
Two patients with other antibodies targeting extracellular
epitopes [AMPAR and GABAB(R)] were not considered in the
statistical analysis but for Figure 3 to illustrate the biomarker
and MRI timeline an AE patients. See Table 1 for the different
AE cohorts used per biomarker. We had follow up data in 13
patients. All other patients (samples) were categorized into either
initial/acute phase or under treatment.
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TABLE 1 | Epidemiological data.
Biomarker Antibody Initial [age/sex] Follow up [age/sex]
Progranulin NMDAR 6 [28.9/6:0] 17 [27.1/16:1]
Caspr2 8 [61.9/2:6] 5 [67.1/0:5]
Lgi-1 7 [69.0/5:2] 6 [63.2/3:3]
T-Tau NMDAR 3 (38.7/3:0] 3 (38.7/3:0]
Caspr2 5 [69.6/0:5] 5 [69.6/0:5]
Lgi-1 3 [63.7/2:1] 3 [63.7/2:1]
Nfl NMDAR 3 (38.7/3:0]* 13 (30.2/12:0]
VGKC-group
{ Caspr2 6 (68.3/1:5] 5 [67.1/0:5]
Lgi-1 3 [63.7/2:1] 3 [63.7/2:1]
Control group young None 24 [29.9/18:6] *
Control group old None 21 [60.0/9:12] *
*not part of statistics
sex = female:male
Overview of the single groups tested in this study. Number of patients included in bold,
sex and mean age are listed.
Magdeburg Group
Patients with AE who were identified and treated in Magdeburg
(n = 13) build a special cohort, because we could e.g., compare
serial MRIs to look for AE caused lesions, basic CSF parameters,
the outcome with the modified Rankin scale, t-tau, and other
biomarker levels in the CSF and ab titer. The modified Rankin
scale in this cohort was assessed by two experienced neurologist
(PK, DB). Six out of thirteen had a paraneoplastic origin and one
patient a postinfectious origin of the AE.
CSF-Neurofilament Light Chain Measurements
We divided the AE cohort into three groups regarding the CSF-
NfL measurements in order to be able to perform a sufficient
statistical analysis (see Table 1). One group with voltage-gated
potassium channels (VGKC) mediated AE (comprising the
Caspr2 and Lgi-1 patients) subdivided in an “initial” (n= 9) and
“under treatment,” meaning after several immunosuppressive
therapies, subgroup (n = 8) and one group with NMDA patients
under treatment (n= 13) (see Table 1 and Figure 1). There were
not enough NMDA patients who would fit into an initial/acute
phase group (n = 3). Therefore, this group could unfortunately
not be part of the statistical analysis.
Neurofilament light chain was measured with a commercial
ELISA (Umandiagnostics, Sweden, catalogue number 10-7001
CE). The sensitivity of this assay is 31 pg/ml. The cut-off for
pathological levels was set at 3523 ng/ml (mean (1823[ng/ml]) +
2 standard deviation (850[ng/ml]) above). Intraessay coefficient
of variance is 7.4% and interessay coefficient of variance is
6%. NfL is a stable protein, which can be measured in the
CSF even though the sample was on room temperature for up
to 8 days (25). Therefore, we could measure NfL in samples
not collected at Magdeburg, We used an already established
control group at Magdeburg (n = 34, mean age = 64.4, CSF-
NfL= 1823 ± 850 [ng/ml]) comprising patients with other
than neuroinflammatory or neurodegenerative diseases (e.g.,
headache, suspicion of infection in the CNS etc.).
FIGURE 1 | CSF Progranulin levels [pg/ml] in patients with AE (n = 36)
measured divided by antibody and by phase of disease (initial vs. under
treatment). Significant results are marked with a *. Normal range is marked in
light red. Line represents the median and the error bars represent the
interquartile range. Black points are outliers.
Total-Tau Measurements
The correct measurement of t-tau due to manufacturer’s
instructions requires different than standard processing of the
CSF samples to create a cell-free sample excluding this parameter
from a retrospective study. We yielded t-tau levels only in
the Magdeburg group, as t-tau is part of the routine in
Magdeburg but not in the other centers involved. Total-Tau
levels were determined using a commercially available single-
parameter ELISA kit [Innogenetics, Ghent, Belgium, catalogue
numbers: 81572 (962-CE) and 81573] established in our routine
diagnostical work up. Intraessay coefficient of variance is
13.2% and interessay coefficient of variance is 11.5%. The
pathological levels were considered according to themanufacture
guidelines.
CSF-Progranulin Measurements
We measured PGRN in CSF and serum of 36 Patients with AE.
We divided our AE cohort (n = 36) into three groups according
to the antibody causing the limbic encephalitis when looking
statistically at the CSF-PGRN levels: one Lgi-1 group (n = 10,
mean age = 69.2), one Caspr2 group (n = 8, mean age = 61.9)
and a NMDAR group (n = 18, mean age = 27.1). These
three groups were subdivided into two subgroups respectively
one before and one after initiating immunosuppressive therapy
(again, called “initial” or “under treatment”) (see Table 1 and
Figure 2).
A commercial ELISA was performed to determine the
levels of PGRN (Human Progranulin ELISA Kit, Mediagnost,
Reutlingen, Germany, catalogue number E103) according to the
manufacturer’s instructions. Intraessay coefficient of variance is
4.4% and interessay coefficient of variance is 8.0%.
We established two control groups for PGRN measurements.
Since PRGN levels are age dependent, we build a younger
control group (n = 24; mean age 29.3 years; 18–40yrs)
and one older group (n = 39; mean age 66.3 years,
Frontiers in Neurology | www.frontiersin.org 3 September 2018 | Volume 9 | Article 668
Körtvelyessy et al. Biomarkers & AE
FIGURE 2 | CSF-Neurofilament light chain (NfL) levels divided into three
possible groups (NMDA under treatment n = 14, VGKC initial n = 7 and under
treatment n = 6) as box plots (number of measurements, n = 30). The area in
light red marks the normal range. Please note that all levels are inside the
normal range. Line represents the median and the error bars represent the
interquartile range. White points mean outlier and star extreme outliers.
50–75 years) and correlated it to age. The patients from
these control groups had other neurological diseases than
neuroinflammatory or neurodegenerative (e.g., acute headache,
excluding neuroinflammatory diseases, no epilepsy patients).
CSF-PGRN level was considered pathological, when the CSF-
PGRN levels per control group were two standard deviation
above or below the mean for each control group respectively.
Antibody Detection
Antibody detection was either performed at the antibody
laboratory Bielefeld, at the University Hospital Schleswig-
Holstein, Department of Neuroimmunology Kiel and Lübeck
or at the Institute of Molecular and Clinical Immunology
Magdeburg. Standard indirect immunofluorescence tests
were performed on antigen-specific transfected Hek293
cells as commercially available and used in clinical routine
(EUROIMMUN, Lübeck, Germany, catalogue numbers: FA
112d-1003-6, FA 112d-1003-51, FA 1430-1003-1) for each
patient revealing the specific antibody and the titer in CSF and
serum.
Statistics
Statistics were calculated by SPSS 21.0 (IBM, Seattle, USA).
Since group size and variances were not equal non-parametric
tests were applied. For comparison of more than two different
groups Kruskal-Wallis test was used with tamhanes post-hoc
analysis. Group comparison of two groups was analyzed with
Mann-Whitney-U test when they were independent and with
the Wilcoxon test when the samples were paired to each
other. For correlational analysis of serum and CSF PGRN
Spearmann-rho correlation was applied. Tests were considered
significant when reaching p < 0.05. There was no test for outliers
applied.
RESULTS
Cohorts
Since the CSF-PGRN level is age-dependent we established
a younger control group aged 18–40 years (n = 24, CSF-
PGRN= 0.72 ± 0.17 ng/ml, Serum-PGRN = 36.4 ng/ml, mean
age = 29.3 years) and a control group 50-75 years (n = 39, CSF-
PGRN = 0.94± 0.22 ng/ml, Serum-PGRN = 28.5 ng/ml mean
age = 66.3 ± 9.8 years). Spearman correlation statistics revealed
a significant correlation between CSF-PGRN and age (r = 0.275,
p= 0.02).
In the Magdeburg group 9/13 had a FLAIR-intense signal
in the limbic system on the MRI. Five out of thirteen patients
developed a hippocampal sclerosis due to AE (see Table 2
and Figure 3). Every patient with pathologically elevated t-tau
levels developed a hippocampal sclerosis. The one patient, who
developed a hippocampal sclerosis without elevated t-tau levels
but elevated NfL concentrations, was administered after he was
already treated and had a hippocampal sclerosis. Therefore the
CSF was taken and measured ∼8 months after beginning of the
AE and treatment. On the contrary only 4 out of 7 patients
with pathological NfL levels developed a hippocampal sclerosis.
Every marker of neurodegeneration and the modified Rankin
scale (mRS) decreased after initializing the immunosuppressive
treatment paralleled by a decrease in antibody titre (see Figure 3
for examples and Table 2 for the follow up data).
Neurofilament Light Chain
NfL was pathologically high (>3523 pg/ml) in 7/23 patients at
different stages of the AE (see Figures 2, 3 and Table 2). Out
of these seven patients, four had a paraneoplastic origin of the
AE and one a postinfectious origin. Furthermore, 5/7 patients
had a FLAIR-intense signal in the limbic areas on the MRI,
which normalized during immunosuppressive treatment. This
decrease in FLAIR signal was mirrored by a decrease in NfL-
levels reaching normal NfL levels during disease course (see
Figure 3 and Table 2). Three out of five patients who developed
hippocampal sclerosis had elevated CSF-NfL levels additionally
to the also elevated t-tau. Solely elevated CSF-NfL was found in
4 patients. We correlated the leukocyte count to the NFL levels
in the Magdeburg cohort and found no correlation (Spearmans
r = 0.625).
There was a trend toward a lower NfL in the NMDA
under treatment group (CSF-NfL = 1455 [pg/ml], range 142–
6841[pg/ml]) compared to the VGKC under treatment group
(CSF-NfL = 2164 [pg/ml], range 821–4039 [pg/ml]) (Mann-
Whitney U test p = 0.052 Z = −1.941), while there was no
difference comparing the VGKC subgroups initial vs. under
treatment (Wilcoxon test p= 0.735 and Z=−0.338).
Total Tau
Looking at the initial t-tau in our patients (before initiating the
treatment) revealed a pathologically high t-tau in 4 patients (see
Table 2). All 4 patients had MRI-FLAIR intense signals in the
temporal lobe/limbic system and subsequently a hippocampal
sclerosis. Immunosuppressive treatment did show an effect on
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TABLE 2 | Biomarkers in the Magdeburg cohort.
Antibody Titer Age Year T-tau NFlight CSF-PGRN Serum-PGRN Cell count mRS Comment
CSF/Serum Onset pg/ml ng/ml pg/ml pg/ml CSF
>370 >3488 <0.54–1.4> <18–54> < 4 cells/mm2
Patient 1 Caspr2 1:128/1:32000 60–65 2013 253 12342 0.76 n.a. 3 5 Temporal FLAIR-intense signal
none/1:375 2015 133 2152 0.8 32.5 0 3 Paraneoplastic origin
none /1:128 2015 108 2055 0.61 30.62 1 3 Hippocampal sclerosis
Patient 2 Caspr2 1:64000/1:750000 75–80 2014 # 292 2047 1.02 27.11 13 5 Temporal FLAIR-intense signal
1:6000/1:96000 2015 213 2123 0.87 30.63 17 1
Patient 3 Caspr2 1:320/1:3200 70–75 2015 # 367 4536 0.84 21.94 0 1 Normal MRI
1:320/1:3200 2015 # 328 3580 0.74 22.05 3 1
Patient 4 Caspr2 1:3200/1:1000 70–75 2016 # 314 3705 0.95 35.18 6 5 Temporal FLAIR-intense signal
1:10 /1:2000 2016 317 4039 0.82 51.57 2 1
Patient 5 Caspr2 1:320/1:4000 66–70 2017 # 349 2159 1.01 32.04 5 4 Normal MRI
1:8/1:1000 2017 375 2586 0.82 43.58 2 0
Patient 6 Lgi-1 none/1:100 60–65 2015 # 796 2128 0.63 32.97 1 3 Temporal FLAIR-intense signal
none/1:32 2015 >11 2493 0.54 38.92 0 0 Hippocampal sclerosis
Patient 7 Lg-1 1:2/1:1000 65–70 2017 # 128 993 0.74 19.97 1 3 Paraneoplastic origin
none/1:320 2017 149 1273 0.73 23 0 0
Patient 8 Lgi-1 1:2 /1:160 60–65 2017 # 197 1582 0.65 27.33 0 3 Temporal FLAIR-intense signal
1:20/1:10 2017 161 1233 0.68 30.12 2 0
Patient 9 NMDA 1:32/1:320 25–30 2010 # 141 n.a. 0.76 29.11 1 5 Paraneoplastic origin
1:10/1:100 2014 105 390 0.89 33.06 3 1
1:1/none 2015 58 553 1.3 n.a. 2 1
Patient 10 NMDA 1:40/1:80 25–30 2016 # 869 38650 1 23.08 7 5 Temporal FLAIR-intense signal
1:10/1:5 2016 229 20736 0.71 17.86 6 2 Hippocampal sclerosis
1:5/1:5 2017 68 6841 0.71 25.43 3 1 Postinfectious origin
Patient 11 NMDA none/1:10 60–65 2014 # 801 28791 1.53 35.51 96 4 Hippocampal sclerosis
none/1:10 2014 372 42286 1.19 32.9 43 0 Temporal FLAIR-intense signal
none/none 2015 192 3975 0.96 35.4 9 0 Paraneoplastic
Patient 12 GABA(B)R 1:320/1:32 50–55 2016 # 135 32029 1.79 37.21 47 5 Paraneoplastic origin
1:320/1:1 2016 168 21439 1.03 37.5 1 3 Temporal FLAIR-intense signal
none/1:10 2016 126 3581 0.95 n.a. 1 2
Patient 13 AMPA 1:32/1:3200 70–75 2014 # 1950 32151 2.47 34.21 43 5 Paraneoplastic origin
1:8/1:375 2014 1984 20354 1.23 38.22 90 4 Temporal FLAIR-intense signal
1:1/none 2015 173 2892 0.7 n.a. 3 2 Hippocampal sclerosis
# Before treatment
n.a. Not available
Complete list of all 13 patients in the cohort where follow up data is available including antibody, antibody serum titer, age, year at which the sample has been obtained, Neurofilament
light chain (NfL), Total-tau (T-Tau), CSF-Progranulin (PGRN), Serum-Progranulin, cell count, modified Rankin scale (mRS) and comments on MRI abnormalities and putative pathogenesis;
n.a., not available; #, timepoint before start of the immunosuppression.
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FIGURE 3 | Three examples of patients from the Magdeburg cohort (patient 5, 12, and 13 see Table 1) showing the under treatment MRI together with the
CSF-Neurofilament light chain (NfL), CSF-Progranulin (PGRN), and Total tau. Normal levels are marked in green at the y-axis and pathological levels are marked in red.
Notice the hippocampal sclerosis in the Lgi-1 patient and the complete recovery from the oedema in the GABA(B)R-AE-patient without a clear sign of a hippocampal
atrophy. The third patient has a AMPAR-AE. The follow up in this patient shows a severe bilateral hippocampal atrophy. Nevertheless the patient improved over years.
the modified Rankin scale and also resulted in a decrease of t-
tau in these patients. The FLAIR signal also decreased in these
patients (see Figure 3). In the other 8 patients without elevated
t-tau levels immunosuppressive therapy had no effect on t-tau
levels. A concomitant tumor had no impact at all on the t-tau
levels. (see Table 2).
Progranulin
The mean CSF-PGRN levels were pathologically high in the
initial NMDAR-group (CSF-PGRN=1.55 ± 1.1 ng/ml) reaching
significance when compared to the NMDAR under treatment
group (Mann-Whitney-U test Z = −2.5 and p = 0.012) and
also when compared to the age-matched healthy group (Mann-
Whitney-U test Z = −2.689 and p = 0.007). Serum PGRN levels
were inside normal ranges in every AE patient and did not
change after immunosuppression (see Figure S1). CSF-PGRN
and CSF-Serum ratios ranged from 0.01 to 0.1, still CSF-PGRN
is show to originate from the CNS when measured in the CSF
(26, 27) We also could not find a correlation between Serum-
PGRN and CSF-PGRN in all groups (Spearman-rho coefficient
r = 0.17, p = 0.3) (Figure S1 in the Supplement).After initiating
the immunosuppressive therapy CSF-PGRN dropped to normal
levels (CSF-PGRN= 0.75± 0.2 ng/ml) in the “under treatment”-
group.
Mean CSF-PGRN levels were normal in the Lgi-1 “initial”
group (CSF-PGRN = 0.71 ± 0.11 ng/ml) and in the under
treatment group (CSF-PGRN = 0.72 ± 0.12 ng/ml) (see
Figure 1). Comparing these results to the age-matched group
revealed significant differences (Kruskal-Wallis test: for “initial”
PGRN: p = 0.009, X2 = 9.4, for follow-up: p = 0.04, X2 = 6.3).
There were significantly lower levels in tamhane post-hoc in
the Patients with AE (Lgi-1 initial vs. control p = 0.009 and
p = 0.041 for the under treatment vs. control) The CSF-PGRN
levels in both Caspr2 groups were inside the normal range (mean
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CSF-PRGN initially = 0.75 ± 0.23 ng/ml and mean CSF-PGRN
under treatment = 0.8 ± 0.16 ng/ml) without significant results
when compared to the age-matched controls (Caspr2 initial vs.
under treatment p= 0.35 and Caspr2 under treatment vs. control
p = 0.92). There was no difference between the “initial” and
the “under treatment” group in the Lgi-1 and Caspr2 cohorts,
respectively.
Follow Up Data
In summary, in all cases with an elevated biomarker of
neurodegeneration in the CSF a decrease of biomarkers, ab titres,
and mRS was observed following immunosuppressive treatment
in all patients (see Table 1 and Figure 3) regardless if the origin
was postinfectious, paraneoplastic, or cryptogenic. There were
two patients with all biomarkers simultaneously elevated. None
of these parameters could predict a hippocampal sclerosis for
sure on the one hand; on the other hand every patient who
developed a sclerosis had either elevated t-tau or NfL levels with
t-tau appearing to be more predictive.
DISCUSSION
We could show for the first time that biomarkers of
neurodegeneration originating from CNS are mirroring
the clinical and probably neuroimmunological course of
patients suffering from AE associated with antibodies to
extracellular epitopes. CSF-PGRN is elevated in patients
with NMDAR-AE during the acute phase. Furthermore,
biomarkers of neurodegeneration such as t-tau together with
CSF-NfL in Patients with AE might be predictive of the
clinical outcome especially for developing a hippocampal
sclerosis. The pathologically elevated biomarkers correlated
with the mRS, the clinical course and the antibody titre.
Besides Progranulin in acute NMDAR-AE, NfL, PGRN and
t-tau did not seem to be restricted to one special autoantibody
mediated AE. This may be due to the fact that the neuronal
and axonal damages in general are mirrored and not the
distinct pathomechanisms of each putative pathological
autoantibody.
Neurofilament Light Chain
NfL has been proven as an excellent marker of axonal loss
(28). It seems very unlikely and there has been no data
on whether peripheral tumors such as teratomas nor other
neuroendocrine tumors can influence the CSF-NfL levels as
possible confounders in our study. The co-occurrence of MRI
changes, hippocampal sclerosis, and elevated NfL levels in our
Magdeburg cohort is pointing at a pathomechanism causing
the edema and subsequently the FLAIR signal resulting in the
axonal dysfunction and subsequently increased NfL levels in the
CSF. Other than in neurodegenerative diseases such as FTD
(29, 30) the axonal loss in AE ceases after initiating sufficient
immunosuppressive therapy as seen by the group of Pranzatelli in
pediatric patients with opsoclonus-myoclonus syndrome caused
by antibodies with intracellular epitopes (22, 23). Constantinescu
et al. also measured CSF-NfL in four Patients with NMDAR-
AE with AE and one Lgi-1 patient (19). Three NMDA-patients
had a status epilepticus and highly pathological CSF-NFL levels,
which has been seen in SE for nearly every marker of neuronal
death (20, 21). In our cohort none had a status epilepticus
confounding the biomarkers. This is possibly the reason why
we found normal CSF-NfL levels in all measured Patients with
NMDAR-AE except for the one with postinfectious origin. The
meningoencephalitis with subsequent neuronal and axonal loss
before the AE might be a reason for the elevated NfL levels in
this patient since the infection was only 7 weeks apart from the
AE. Our results are also much more in line with the known
pathomechanism in NMDAR- AE (31, 32) where only marginal
neuronal damage occurs and the main reason for the clinical
symptoms is most likely the internalization of the NMDA-
receptor. The one Lgi-1 patient (without SE) in the cohort of
Constantiescu et al had normal NfL levels as our entire Lgi-1
group.
Total-Tau is a better marker for neuronal death as NfL (see
below). However, FLAIR intense signals in the hippocampus as a
consequence of disturbances of neuronal membrane function did
correlate with NfL levels in our small cohort.
Total-Tau
Total-tau is an excellent marker for neuronal death (21,
33) 4/5 patients who developed a hippocampal sclerosis
had pathological elevated t-tau levels in our Magdeburg
cohort (n = 13). This is well in line with the current
concept of the pathomechanisms leading to a sclerosis (34).
Although, patient 1 (see Table 2) with the Caspr2 AE who
was already treated months before admission to Magdeburg
had only elevated CSF-NfL and normal t-tau levels and a
hippocampal sclerosis (see Table 2). Sadly, it was not possible
to measure NfL and t-tau levels in this patients initial
CSF.
In sum, the measurement of t-tau may be a good marker
before treatment decision in suspected autoimmune encephalitis
or before deciding on the further immunosuppressive treatment
but is limited to laboratories with expertise in measuring t-tau.
Progranulin
PGRN is playing a role in autoimmune mediated diseases such as
rheuma or bowel disease or status epilepticus or in suppression of
neuroinflammation (30, 35–37) Recently, EpiphrinA2 as a part
of the Ephrin receptor kinase has been identified as functional
receptor of PGRN and the potential of PGRN phosphorylating
and activating the EpiphrinB2 receptor (38) linking it to the
dysfunction in the EpiphrinB2 pathway known in AE mediated
by autoantibodies against the NMDA-receptor (39, 40). The
distribution in the fronto-temporal structures (41), the possible
common link with the AE mediated by NMDAR via the
EpiphrinA2-EpiphrinB2 pathway and the known role as a
mediator in neuroinflammation and autoimmunitymakes PGRN
an interesting protein in AE.
We detected elevated CSF-PGRN levels in our NMDA-
patients with a severe ongoing AE. On the other hand, CSF-
PGRN was low in patients suffering from Lgi-1-AE sometimes
reaching levels of FTD patients (29) in contrast to Patients
with NMDAR-AE and controls. The significance of this low
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CSF-PGRN is doubtful because none of the CSF-PGRN levels
normalized after initiating the immunosuppressive therapy. Also
most CSF-PGRN levels in the patients with Lgi-1-AE were still
inside the normal range.
When looking at the t-cell or b-cell specific cytokine patterns
in the patient’s CSF suffering from NMDAR-AE several groups
have seen a massive b-cell predominant cytokine pattern in
the beginning especially in CXCL-13 levels (42, 43) and then a
decrease in follow up. Also, cytokine pattern associated with t-cell
activation were detectable throughout the course of AE without
relevant changes. This course in cytokine levels could explain the
elevated Progranulin levels in patients having acute NMDAR-AE.
PGRN in Serum and CSF was not elevated in patients with AE
due to paraneoplastic origin although PGRN is also known as a
tumor marker for certain tumors such as Lymphomas (44) The
missing correlation between the serum-PGRN and CSF-PGRN is
pointing at a cerebral origin of the CSF-PGRN as already seen
in other diseases (26, 27). Overall, this result is probably due to
an affection of the CSF-PGRN pathway in acute NMDAR-AE
but needs more in vivo and in vitro experiments to be further
examined.
One major limitation of the study is the small sample size in
every subgroup tested. This fact is due to the very low numbers
of patients with AE overall. Although total numbers are too small
to draw a final conclusion the t-tau levels together with the CSF-
NFL levels seem to best characterize the stage of neuronal death
in the brain. The diagnostic value of NFL levels in the CSF should
be evaluated in further studies. Another limitation is that we
only had follow up data in 13 patients limiting our knowledge
about MRI, mRS, and ab titres. Another limitation of the study
is that due to the scarcity of the diseases measurements of the
biomarkers could not be done in a batch but on demand.
A larger study should be conducted to further elucidate
the correlation of these interesting parameters how they could
contribute to therapeutic decisions.
CONCLUSION
NfL, t-tau and PGRN could be potential biomarkers of neuronal
or axonal loss in patients suffering from AE. Especially, the
Patients with NMDAR-AE have elevated PGRN levels at the acute
phase of the AE. This fact further strengthens the hypothesis
of a pathological change in the Epiphrin receptor metabolism
in NMDAR patients. CSF-PGRN may be a marker for acute
NMDA-AE.
Furthermore, we strongly recommend measuring NfL and t-
tau in the CSF of every patient with AE although one biomarker
for itself could not predict all hippocampal sclerosis in this pilot
study. Pathological levels of a biomarker of neurodegeneration
should be considered as an on-going AE and may be taken into
account when planning further therapy.
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